A
Alcista
Alcista · 25%DBVT
$5.31
Precio del escenario
$9.620
+0.142 (+1.48%)Al cierre
Loading chart…
- Máximo
- 9.918
- Apertura
- 9.530
- Precio medio ponderado por volumen
- 9.69
- Volumen
- 1.41M
- Capitalización
- 81.60M
- Mínimo
- 9.530
- Importe
- 13.66M
- EV/EBITDA, TTM
- -0.09
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
Análisis de IA of Dbv Technologies SA (DBVT)
MantenerDBV Technologies is currently not a strong buy due to its low price of $9.05 and a very low RSI of 24.871, indicating oversold conditions. However, the company has a strong gross margin of 100% and significant cash reserves of $174.9 million, which provide some stability. The main risk is its negative net income, which reached -$50.4 million in Q2 2026, indicating ongoing financial challenges.
Recomendaciones de analistas (9)
+382.33% de potencial alcista
Comprar
8 Comprar
1 Mantener
0 Vender
Actual: 9.62
Mínimo
40.00
Promedio
46.40
Máximo
51.00
H.C. Wainwright
Comprar
$40
2026-06-30
H.C. Wainwright
2026-06-30
Precio objetivo
$40
Comprar
Cantor Fitzgerald
Sobreponderar
$48
2026-06-30
Cantor Fitzgerald
2026-06-30
Precio objetivo
$48
Sobreponderar
Citizens
Superar al mercado
$55
2026-06-30
Citizens
2026-06-30
Precio objetivo
$55
Superar al mercado
Citizens
Superar al mercado
$55
2026-05-01
Citizens
2026-05-01
Precio objetivo
$55
Superar al mercado
Goldman Sachs
Vender
—
2026-04-09
Goldman Sachs
2026-04-09
Precio objetivo
—
Vender
Métricas de valoración
El PER previsto actual de Dbv Technologies SA (DBVT) es 0.00, frente a su media de 5 años de -3.76.
Escenarios de precio de Alphio AI para DBVT
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con DBVT en cartera
Cronología de eventos
Noticias
7.009-02NewsfilterCompany Voting Rights and Total Shares Information
2.009-02Yahoo FinanceDBV Technologies Voting Rights and Shares Information
8.507-30GlobenewswireDBV Technologies Sells $50 Million ADSs via ATM Program
- 8.507-17Newsfilter
DBV Technologies Files ATM Prospectus for Up to $150 Million
9.507-16seekingalphaDBV Technologies Q2 Earnings Beat Expectations
Preguntas frecuentes sobre DBVT, respondidas por Alphio AI
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
DBV Technologies is currently not a strong buy due to its low price of $9.05 and a very low RSI of 24.871, indicating oversold conditions. However, the company has a strong gross margin of 100% and significant cash reserves of $174.9 million, which provide some stability. The main risk is its negative net income, which reached -$50.4 million in Q2 2026, indicating ongoing financial challenges.
9 analysts cover DBVT: 8 rate it Buy, 1 Hold and 0 Sell. The average price target is 46.40.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.